Biomarker Testing Matters

In recent years, biomarker testing has become an increasingly valuable resource for people diagnosed with gastric cancer. It is a gateway to personalized treatments that can often improve patient outcomes.

Cancer cell biomarkers are genes, gene mutations or proteins that cause cancer to grow and spread to other locations. It is important to check for specific stomach cancer biomarkers because some new therapies can target them and potentially stop cancer growth.

"Most experts in the field of stomach cancer would recommend that every patient with stomach cancer have their tumor tested for what we would consider the most common and most relevant biomarkers right now," says Dr. Jeremy Davis, a leading surgical oncologist who specializes in gastrointestinal cancers at the National Institutes of Health (NIH). Read more...

Test Your Biomarkers

The Gastric Cancer Foundation is proud to be a founding supporter of Test Your Biomarkers - a national education and awareness initiative to inform people about the importance and availability of biomarker testing in the treatment of stomach cancer.

Learn More about Biomarkers

Be Part of Advancing Research

If you are a person with gastric cancer - or a close family member - enrolling in the Gastric Cancer Registry will help drive future discoveries. Your participation can make an important difference in the search for a cure.

LEARN ABOUT THE REGISTRY

Tips for Travel

For many of us, June marks the beginning of Summer - with travel and family fun on the horizon. Chef Hans Rueffert helps you navigate your new digestive needs while away from home.

Travel

Chef Hans and Dr. Ellen Steinberg share some tips and laughs while they discuss nutritional obstacles that one can face while traveling.

Fast Food

Dr. Steinberg joins Hans to discuss the many ways to navigate fast food or prepared food eating.

Dining Out

Chef Hans heads to a restaurant to talk tips on how to order “smart” when dining out with friends and family.

Research Roundup

Progress in the understanding of gastric cancer development and treatment continues. Here are a few highlights in recent news:

At ASCO, Bold Therapeutics announced positive results from a phase 2 study of its first-in-class experimental drug BOLD-100 in gastric cancer. The drug is being tried in combination with chemotherapy.

A study of individuals with the hereditary condition Lynch Syndrome found that the risk of gastric cancer increases significantly at age 70 among individuals with three specific gene variants, leading the researchers to suggest that studies be done to investigate the cost-effectiveness of routine screening for the disease among this population.

A Canadian research team discovered how H. pylori sticks to the lining of the stomach–a finding they believe could inform the development of vaccines to fight the bacteria, which raises the risk of gastric cancer.

Quick Links to Resources

JOIN THE REGISTRY

FIND CLINICAL TRIALS

OUR ONLINE COMMUNITY

Special Thanks to Our

National Sustaining Sponsors

Spread the word. Share the Gastric Cancer Foundation Newsletter.

Share This Email

DONATE